


Derivatives of *N*-Heterocyclylmethylbenzamides, preparation method thereof and application of same in therapeutics

- 5 The subject of the present invention is *N*-heterocyclylmethylbenzamide derivatives, their preparation and their therapeutic application.

The compounds of the invention correspond to general
10 formula (I)



in which

- R represents a hydrogen atom or a vinyl group;
n represents 0 or 1 or 2 when R represents a hydrogen
15 atom and n represents 1 when R represents a vinyl group;
X represents a group of formula CH or a nitrogen atom when R represents a hydrogen atom and X represents a group of formula CH when R represents a vinyl group;
20 R₁ represents either a phenyl or naphthyl group optionally substituted with one or more substituents chosen from halogen atoms, linear or branched (C₁-C₆)alkyl, hydroxyl and (C₁-C₆)alkoxy groups, the trifluoromethyl group, or a cyclohexyl group, or a
25 heteroaryl group chosen from the thienyl, pyridinyl, oxazolyl, furanyl, thiazolyl, quinolinyl, and

isoquinolinyl groups;

R_2 represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and the trifluoromethyl, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, thienyl, phenyloxy, hydroxyl, mercapto, thio (C_1-C_6) alkyl and cyano groups or a group of general formula $-NR_4R_5$, $SO_2NR_4R_5$, $-SO_2-(C_1-C_6)$ alkyl, $-SO_2$ -phenyl, $-CONR_4R_5$, $-COOR_7$, $-CO-(C_1-C_6)$ alkyl, $-CO$ -phenyl, $-NHCOR_8$, $-NHSO_2-(C_1-C_6)$ alkyl, $-NHSO_2$ -phenyl and $-NHSO_2NR_4R_5$ or a group of formula $-OCF_2O$ attached at the 2- and 3-positions of the phenyl group;

the groups (C_1-C_6) alkyl, (C_1-C_6) alkoxy, $-SO_2-(C_1-C_6)$ alkyl, $-CO-(C_1-C_6)$ alkyl and $-NHSO_2-(C_1-C_6)$ alkyl being optionally substituted with one or more groups R_3 ;

the groups phenyl, $-SO_2$ -phenyl, $-CO$ -phenyl and $-NHSO_2$ -phenyl being optionally substituted with a group R_6 ;

R_3 represents a halogen atom, or a phenyl, (C_1-C_6) alkoxy or $-NR_4R_5$ group;

R_4 and R_5 represent, independently of each other, a hydrogen atom or a (C_1-C_6) alkyl group or R_4 and R_5 form with the nitrogen atom bearing them a pyrrolidine ring, a piperidine ring or a morpholine ring;

R_6 represents a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group, a hydroxyl group, a mercapto group, a (C_1-C_6) alkyl or (C_1-C_6) alkoxy group;

R_7 represents a hydrogen atom or a (C_1-C_6) alkyl group optionally substituted with one or more groups R_3 , or a phenyl group optionally substituted with a group R_6 ;

R_8 represents a (C_1-C_6) alkyl group optionally substituted with one or more groups R_3 , or a (C_1-C_6) alkoxy group, or a phenyl group optionally substituted with a group R_6 .

Among the compounds of general formula (I), a number of subgroups of preferred compounds can be distinguished:

group 1: compounds of threo configuration and of general formula (I) in which n represents 0 or 1;

group 2: compounds of group 1 in whose formula X represents a group of formula CH;

group 3: compounds of group 2 in whose formula R
5 represents a hydrogen atom;

group 4: compounds of group 3 in whose formula n represents 1;

10 group 5: compounds according to group 4 in whose formula R₁ represents an optionally substituted phenyl group.

The compounds of formula (I) may contain several
15 asymmetric centers. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers and mixtures thereof, including the racemic mixtures, form part of the invention.

20 More particularly, the compounds of formula (I), for which R = H, can exist in the form of threo ((1S,2S) and (1R,2R)) or erythro ((1S,2R) and (1R,2S)) diastereoisomers or of pure enantiomers or as a mixture of such isomers.

25

The compounds of formula (I) can exist in the form of bases or of addition salts with acids. Such addition salts form part of the invention.


These salts are advantageously prepared with
30 pharmaceutically acceptable acids, but the salts of other acids useful, for example, for the purification or isolation of the compounds of formula (I) also form part of the invention. The compounds of formula (I) can also exist in the form of hydrates or solvates, namely
35 in the form of associations or combinations with one or more molecules of water or with a solvent. Such hydrates and solvates also form part of the invention.

The compounds of the invention exhibit a particular

activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2.

The compounds of general formula (I) may be prepared by
5 a method illustrated by scheme 1 which follows.


Scheme 1



10 According to scheme 1, a diamine of general formula (II), in which n , X , R and R_1 are as defined above, is coupled with an activated acid or an acid chloride of general formula (III) in which Y represents a leaving group, such as a halogen atom, and R_2 is as defined
15 above, using methods known to persons skilled in the art.

The diamines of general formula (II), in which $\text{R} = \text{H}$ and n , X and R_1 are as defined above, may be prepared by
20 a method illustrated by scheme 2 which follows.

Scheme 2



25 The ketone of general formula (IV), in which n , X and R_1 are as defined above, is reacted with benzyloxy-

hydroxylamine hydrochloride, at the reflux temperature of pyridine, in order to obtain the oxime of general formula (V). The two forms *Z* and *E* of the oxime may be separated according to methods known to persons skilled in the art such as chromatography on a silica gel column.

The oxime (V), preferably in the *Z* hydrochloride form, is then reduced at the reflux temperature of tetrahydrofuran with lithium aluminum hydride to give the predominantly threo-diamine of general formula (II).


By reducing the *E* form of the oxime of general formula (V), a diamine (II) mixture is obtained in the form of the two diastereoisomers (threo/erythro).

The erythro- and threo-diastereoisomers may be separated according to methods known to persons skilled in the art such as chromatography on a silica gel column.

Another variant preparation of the diamines of general formula (II), in which R and R_1 are as defined above, n is equal to 1 and X is a CH , is illustrated by the scheme 3 which follows.

25

Scheme 3



The alcohols of general formula (VI) are converted to amines by a Mitsunobu reaction according to the method described in *Bull. Soc. Chim. Belg.* (106), 1997, 77-84 and in *Tetrahedron: Asymmetry*, (6), 1995, 1699-1702.

Moreover, the chiral compounds of general formula (I), corresponding to the enantiomers (1R,2R) or (1S,2S) of the threo-diastereoisomer and to the enantiomers (1S,2R) or (1R,2S) of the erythro-diastereoisomer, may also be obtained either by separating the racemic compounds by high performance liquid chromatography (HPLC) on a chiral column, or from the chiral amine obtained either by resolving the racemic amine of general formula (II), by the use of a chiral acid, such as tartaric acid, camphorsulfonic acid, dibenzoyl-tartaric acid, N-acetyl-leucine, by fractional and preferential recrystallization of a diastereoisomeric salt from a solvent of the alcohol type, or by enantioselective synthesis from an erythro- or threo-chiral alcohol using a method similar to that described in scheme 3. The chiral alcohols may be obtained by a method similar to that described in *Tetrahedron*, (55), 1999, 2795-2810. In the case where R represents a vinyl group and R₁ represents a quinolinyl group, the diamine of general formula (II) may be prepared according to scheme 3 using the corresponding commercially available chiral alcohols.

The racemic ketone of general formula (IV) may be prepared either by deprotonation of an activated complex of the bridged cyclic amines and reaction with an electrophile, such as an ester or a Weinreb amide, according to a method similar to that described in *Chem. Commun.*, 1999, 1927-1928, or by reaction of an organometallic compound on the ethyl ester of 2-quinuclidinic acid, according to a method similar to that described in *J. Med. Chem.*, 1980, 180-184, or by oxidation of the corresponding alcohol obtained by various methods similar to those described in *J. Org. Chem.*, 50, 1985, 29-31 and *Chem. Comm.*, 1999, 1927-1929 with oxidizing agents known to persons skilled in the art such as manganese dioxide or the oxalyl chloride-dimethyl sulfoxide system.

The alcohols of general formula (VI) may also be obtained by reducing the corresponding ketones of general formula (IV) under conditions known to persons skilled in the art.

5

The acids and acid chlorides of general formula (III) are commercially available or are prepared by analogy with methods known to persons skilled in the art.

10 For example, 4-amino-3-chloro-5-trifluoromethylbenzoic acid may be prepared by chlorination of 4-amino-5-trifluoromethylbenzoic acid with sulfuryl chloride in a chlorinated solvent such as chloroform, according to a method similar to that described in *Arzneim. Forsch.*,
15 34, 11a, (1984), 1668-1679.

2,6-Dichloro-3-trifluoromethylbenzoic acid may be prepared by methods similar to those described in US 3,823,134.

20

The benzoic acids derived from sulfonamides may be prepared according to methods similar to those described in patents DE-2436263, BE-620741, DE-1158957, US-3112337, GB-915259, US-3203987, DE-642758, EP-68700, 25 FR-2396757, DE-2734270, and in *J. Pharm. Pharmacol.* (1962), 14, 679-685. The meta-chlorosulfonylated acids may be obtained according to a method similar to those described in *J. Chem. Soc. (C)*, (1968), 13, and in patents US-2273444, DE-19929076, EP-0556674.

30

Chlorosulfonylation at the *ortho* or *para* position may be carried out starting with a diazonium salt according to a method similar to that described in patent US-3663615 with 4-amino-3-chlorobenzoic acid.

35

The sulfonamides are obtained by the reaction of the chlorosulfonylated derivatives in the presence of an excess of amine in a solvent such as tetrahydrofuran, at room temperature or under reflux.

The secondary sulfonamides may be methylated according to a method similar to that described in patent BE-620741. The primary sulfonamides may be reacted with
5 an isocyanate, in a solvent such as tetrahydrofuran, in the presence of a base such as potassium carbonate. Some sulfoxide derivatives of benzoic acids are described in patents DE-2056912, DE-2901170 and US-3953476 or may be obtained by methods similar to
10 those described in patent BE-872585 and in *J. Org. Chem.* (1991), 56(1), 4976-4977.

The benzoic acid derivatives of general formula (III), in which R_2 represents a branched alkyl group, may be
15 prepared according to methods similar to that described in patent US-4879426 and in *Syn. Lett.* (1996), 473-474 and *J. Med. Chem.* (2001), 44, 1085-1098.

The benzoic acid derivatives of the biphenyl type may
20 be prepared according to methods known to persons skilled in the art. Finally, the carbonylated benzoic acids may be synthesized according to methods similar to those described in patents US-3725417 and GB-913100 and in *Chem. Pharm. Bull.*, (1988), 36(9), 3462-3467 and
25 *J. Labelled Compd. Radiopharm.*, (1997), 39(6), 501-508.

The esters or amides may be introduced by direct carbonylation with a strong base at the para position of the acid, under the conditions described in
30 *Tetrahedron Lett.*, (2000), 41, 3157-3160.

Finally, the cyano derivatives of benzoic acids are obtained by heating a halogenated benzoic acid or ester in the presence of potassium cyanide, a catalyst of the
35 tetrakis(triphenylphosphine)palladium type, in a solvent of the tetrahydrofuran type, according to a method similar to that described in *J. Org. Chem.* (1967) 62, 25, 8634-8639.

Other acids and acid chlorides of general formula (III) may be obtained according to methods similar to those described in patents EP-0556672, US-3801636 and in *J. Chem. Soc.*, (1927), 25, *Chem. Pharm. Bull.*, (1992), 1789-1792, *Aust. J. Chem.*, (1984), 1938-1950 and *J.O.C.*, 1980), 527.

The examples which follow illustrate the preparation of a few compounds of the invention. The elemental microanalyses, and the IR and NMR spectra, and the HPLC on a chiral column confirm the structures and the enantiomeric purities of the compounds obtained.

The numbers indicated in brackets in the headings of the examples correspond to those of the 1st column of the table given later.

In the names of the compounds, the dash "-" forms part of the word, and the dash "_" only serves for splitting at the end of a line; it is deleted in the absence of splitting, and should not be replaced either by a normal dash or by a gap.

Example 1 (compound No. 3)

threo-2-Chloro-N-[(1-azabicyclo[2.2.2]oct-2-yl)phenylmethyl]-3-trifluoromethylbenzamide hydrochloride 1:1

1.1. (Z)-1-Azabicyclo[2.2.2]oct-2-yl(phenyl)methanone O-benzyloxime hydrochloride

2.2 g (9.35 mmol) of 1-azabicyclo[2.2.2]oct-2-yl(phenyl)methanone (*Chem. Commun.*, 1999, 1927-1928) and 3 g (18.69 mmol) of benzyloxyhydroxylamine hydrochloride in 50 ml of pyridine are introduced into a 100 ml round-bottomed flask equipped with magnetic stirring, and the mixture is heated under reflux for 20 h.

After evaporation of the solvents under reduced pressure, the residue is diluted with water and chloroform, the aqueous phase is separated, and it is
5 extracted with chloroform. After washing the combined organic phases, drying over sodium sulfate and evaporation of the solvent under reduced pressure, the residue is purified by chromatography on a silica gel column, eluting with a mixture of chloroform and
10 methanol.

There are obtained 0.5 g of a fraction corresponding to (*E*)-1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methanone O-benzyloxime and 2.25 g of another fraction
15 corresponding to (*Z*)-1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methanone O-benzyloxime hydrochloride m.p. 195-197°C.

1.2. threo-[1-Azabicyclo[2.2.2.]oct-2-yl(phenyl)-
20 methyl]amine

1.3 g (34.32 mmol) of lithium aluminum hydride in suspension in 10 ml of tetrahydrofuran are placed in a 250 ml three-necked flask equipped with magnetic
25 stirring under a nitrogen atmosphere, 2.2 g (6.16 mmol) of (*Z*)-1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methanone O-benzyloxime hydrochloride are added in portions and the mixture is heated under reflux for 2 h.

30 After cooling, the solution is hydrolyzed at 0°C with successively 1.3 ml of water and then 1.3 ml of aqueous sodium hydroxide at 15% and 3.9 ml of water. The heterogeneous mixture is filtered on Celite®, the filtrate is concentrated under reduced pressure and
35 then the residue is diluted with 1N hydrochloric acid and chloroform. The organic phase is separated and the aqueous phase is basified with aqueous ammonia. It is extracted twice with chloroform. After washing the combined organic phases, drying over sodium sulfate and

evaporating the solvent under reduced pressure, 1.25 g of threo-[1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methyl]-amine are obtained in the form of an oil which crystallizes and which is used as it is in the next
5 step.

Melting point: 120-140°C.

1.3. threo-2-Chloro-N-[(1-azabicyclo[2.2.2.]oct-2-yl)-
10 phenylmethyl]-3-trifluoromethylbenzamide
hydrochloride 1:1

0.51 g (2.12 mmol) of 2-chloro-3-trifluoromethylbenzoic acid chloride in solution in 5 ml of chloroform is
15 placed in a 100 ml round-bottomed flask equipped with magnetic stirring, in the presence of 0.29 g (2.12 mmol) of potassium carbonate at 0°C, and a solution of 0.42 g (1.93 mmol) of threo-[1-azabicyclo-
[2.2.2.]oct-2-yl(phenyl)methyl]amine in solution in
20 5 ml of chloroform is poured in and the mixture is stirred at room temperature for 6 h.

After hydrolyzing with water and diluting with chloroform, the aqueous phase is separated and it is
25 extracted with chloroform. After washing the combined organic phases, drying over sodium sulfate and evaporating the solvent under reduced pressure, the residue is purified by chromatography on a silica gel column, eluting with a mixture of chloroform and
30 methanol. 0.18 g of an oily product is obtained.

The latter is dissolved in a few ml of propan-2-ol, 6 ml of a 0.1N hydrochloric acid solution in propan-2-ol are added and the mixture is concentrated under
35 reduced pressure in order to reduce the volume of the solvent. After trituration, 0.15 g of hydrochloride is finally isolated in the form of a solid.

Melting point: 257-262°C.

Example 2 (compound No. 4)

threo-2,6-Dichloro-N-[(1-azabicyclo[2.2.2]oct-2-yl)phenylmethyl]-3-trifluoromethylbenzamide

5 hydrochloride 1:1

0.36 g (1.38 mmol) of 2,6-dichloro-3-trifluoromethylbenzoic acid, 0.187 g (1.38 mmol) of hydroxybenzotriazole, 0.264 g (1.38 mmol) of 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride in solution
10 in 7 ml of chloroform are introduced into a 100 ml round-bottomed flask equipped with magnetic stirring, and the mixture is stirred at room temperature for 30 min.

15

0.3 g (1.38 mmol) of threo-[1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methyl]amine in solution in 5 ml of chloroform is added and the mixture is stirred at room temperature overnight.

20

After hydrolyzing with water and diluting with chloroform, the aqueous phase is separated and it is extracted with chloroform. After washing the combined organic phases, drying over sodium sulfate and
25 evaporating the solvent under reduced pressure, the residue is purified by chromatography on a silica gel column, eluting with a mixture of chloroform and methanol. 0.37 g of an oily product is obtained.

30 The latter is dissolved in a few ml of propan-2-ol, 20 ml of a 0.1N hydrochloric acid solution in propan-2-ol are added and the mixture is concentrated under reduced pressure in order to reduce the volume of the solvent. After trituration, 0.35 g of hydrochloride is
35 finally isolated in the form of a solid.

Melting point: 270-273°C.

Example 3 (compound No. 14)

2-Chloro-N-(8 α ,9S)cinchonan-9-yl)-3-trifluoromethyl-
benzamide hydrochloride 2:1

3.1. 8 α -9S-Cinchonan-9-amine

5
0.74 g (2.5 mmol) of 8 α ,9R-cinchonan-9-ol
(cinchonidine) and 0.79 g (3 mmol) of triphenyl-
phosphine in suspension in 15 ml of tetrahydrofuran are
introduced into a 100 ml three-necked flask equipped
10 with magnetic stirring, under a nitrogen atmosphere,
and 3.5 ml of a 0.9 M solution of hydrazoic acid in
benzene (3 mmol) are added. A solution of 0.55 ml
(2.75 mmol) of diisopropylcarbodiimide in 1.5 ml of
tetrahydrofuran is added to this solution dropwise and
15 the mixture is heated at 40°C for 16 h.

0.65 g (2.5 mmol) of triphenylphosphine is added and
the mixture is stirred for 30 min, 0.5 ml of water is
added and the stirring is resumed for 6 h.

20
The mixture is hydrolyzed with 1N hydrochloric acid and
diluted with chloroform. The aqueous phase is basified
with aqueous ammonia and it is extracted several times
with chloroform. After washing the combined organic
25 phases, drying over sodium sulfate and evaporating the
solvent under reduced pressure, 0.97 g of an orange-
colored oil is obtained containing 8 α ,9S-cinchonan-9-
amine which is used crude in the next step.

30 3.2. 2-Chloro-N-(8 α ,9S-cinchonan-9-yl)-3-trifluorometh-
ylbenzamide hydrochloride 2:1

According to the method described in Example 1.3,
starting with 0.97 g (3.3 mmol) of 8 α ,9S-cinchonan-9-
35 amine, 0.84 g (3.4 mmol) of 2-chloro-3-trifluoromethyl-
benzoic acid chloride and 0.5 g (3.63 mmol) of
potassium carbonate, 0.360 g of oil is obtained which
is dissolved in 30 ml of 1N hydrochloric acid. The
aqueous phase is extracted with chloroform and then the

solvent is evaporated under reduced pressure. 0.26 g of hydrochloride is thus obtained in the form of a white solid.

Melting point: 185-205°C; $[\alpha]_D^{25} = -5.4$ ($c=0.986$, MeOH).

5

Example 4 (compound No. 17)

2,6-Dichloro-N-[(1S)-[(2S)(1-azabicyclo[2.2.2]oct-2-yl)phenylmethyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1

10

4.1 (1S)-[(2S)-1-Azabicyclo[2.2.2.]oct-2-yl(phenyl)-methyl]amine D-tartrate

15 9.4 g (43.45 mmol) of threo-[1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methyl]amine are dissolved in 150 ml of ethanol. A solution of 6.52 g (43.45 mmol) of D-tartaric acid in solution in 200 ml of ethanol is poured in. After evaporating the solvent under reduced
20 pressure, the residue is placed in 500 ml of a solution of ethanol and of water (9/1) and then heated until dissolution is obtained. After 3 successive recrystallizations, 5.39 g of (1S)-[(2S)-1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methyl]amine D-tartrate are
25 obtained.

Melting point: 125-135°C.

$[\alpha]_D^{25} = -46.1$ ($c=0.616$; MeOH).

4.2. 2,6-Dichloro-N-[(1S)-[(2S)(1-azabicyclo[2.2.2]oct-2-yl)phenylmethyl]-3-(trifluoromethyl)benzamide hydrochloride 1:1

30

3.33 g (12.02 mmol) of 2,6-dichloro-3-(trifluoromethyl)benzoic acid chloride in solution in 30 ml of
35 chloroform are placed in a 100 ml round-bottomed flask equipped with magnetic stirring in the presence of 1.82 g (13.22 mmol) of potassium carbonate at 0°C, and a solution of 2.6 g (12.02 mmol) of (1S)-[(2S)-1-azabicyclo[2.2.2.]oct-2-yl(phenyl)methyl]amine

(obtained by basification of the salt described in 4.1, followed by extraction) in solution in 40 ml of chloroform is poured in and the mixture is stirred at room temperature for 6 h.

5

After hydrolyzing with water and diluting with chloroform, the aqueous phase is separated and it is extracted with chloroform. After washing the combined organic phases, drying over sodium sulfate and
10 evaporating the solvent under reduced pressure, the residue is purified by chromatography on a silica gel column, eluting with a mixture of chloroform and methanol.

5.4 g of an oily product are obtained.

15

The latter is dissolved in a few ml of chloroform, 600 ml of a solution of ether saturated with hydrochloric acid are added, and the mixture is concentrated under reduced pressure. The residue is
20 recrystallized from ethyl acetate. 4.7 g of 2,6-dichloro-N-[(1S)-[(2S)(1-azabicyclo[2.2.2]oct-2-yl)phenylmethyl]-3-(trifluoromethyl)benzamide hydrochloride are thus obtained.

Melting point: 264-268°C.

25 $[\alpha]_D^{25} = +61.1^\circ$ (c=0.32; MeOH)

Example 5 (compound No. 26)

threo-N-[1-Azabicyclo[2.2.2]oct-2-yl(4-fluorophenyl)-methyl]-2,6-dichloro-3-(trifluoromethyl)benzamide
30 hydrochloride 1:1

5.1 1-Azabicyclo[2.2.2]oct-2-yl(4-fluorophenyl)-methanol

35 1.11 g (10 mmol) of quinuclidine in 40 ml of dry tetrahydrofuran at 0°C are placed in a 100 ml three-necked flask under argon. 1.33 ml (10.5 mmol) of ether-boron trifluoride complex are added dropwise and the mixture is stirred for 30 min at 0°C (solution A). In

parallel, 2.47 g (22 mmol) of dry potassium tert-butoxide in 60 ml of dry tetrahydrofuran are placed in a 250 ml three-necked flask under argon. The mixture is cooled to -70°C and 22 ml of a 1M solution of sec-butyllithium in the cyclohexane/hexane mixture (22 mmol) are poured in dropwise while the temperature is kept below -60°C (solution B). At the end of the addition, the solution A is delivered by a cannula-like tube into the solution B while the temperature is kept at around -70°C . The mixture is kept stirring for 2 h.

2.36 mol (22 mmol) of distilled 4-fluorobenzaldehyde in solution in 20 ml of tetrahydrofuran at -70°C are placed in a 50 ml three-necked flask under argon. The solution B is delivered by a cannula-like tube while the temperature is kept at around -70°C . The resulting solution is left for 30 min at -70°C and allowed to rise to -20°C . The mixture is then hydrolyzed with a 10% hydrochloric acid solution. The mixture is extracted with ether and then the aqueous phase is taken up and basified with aqueous ammonia. The mixture is extracted with chloroform and then the solvent is evaporated under reduced pressure. The residue is purified by flash chromatography on a silica gel column, eluting with a mixture of chloroform and methanol. 0.53 g of 1-azabicyclo[2.2.2]oct-2-yl(4-fluorophenyl)methanol is thus obtained in the form of a yellowish solid.

Melting point: $69-70^{\circ}\text{C}$.

30

5.2 1-Azabicyclo[2.2.2]oct-2-yl(4-fluorophenyl)methanone

1.3 ml of dimethyl sulfoxide in 40 ml of tetrahydrofuran at -70°C are placed in a 250 ml three-necked flask under nitrogen, and 0.9 ml of oxalyl chloride (11 mmol) is added dropwise and the mixture is kept stirring for 30 min at this temperature. A solution of 1 g (4.6 mmol) of 1-azabicyclo[2.2.2]oct-2-

yl(4-fluorophenyl)methanol in 40 ml of tetrahydrofuran is added dropwise. After 30 min, 4 ml (27.6 mmol) of triethylamine are added at -70°C. The reaction mixture is then stirred for 30 min at -70°C, for 30 min at 0°C and then for 1 h at room temperature.

The mixture is poured into an aqueous ammonia solution and then extracted several times with chloroform. The organic phases are dried over sodium sulfate and evaporated under reduced pressure. The residue is purified by chromatography on a silica gel column, eluting with a mixture of chloroform and methanol. 1 g of 1-azabicyclo[2.2.2]oct-2-yl(4-fluorophenyl)methanone is thus obtained.

Melting point: 68-69°C.

5.3 (Z)-1-Azabicyclo[2.2.2]octyl(4-fluorophenyl)methanone O-benzyloxime hydrochloride

According to the procedure described in Example 1.1, starting with 1.17 g (5 mmol) of ketone, 1.4 g of (Z)-1-azabicyclo[2.2.2]octyl(4-fluorophenyl)methanone O-benzyloxime hydrochloride are obtained after trituration, in ether, of the residue obtained after the treatment of the reaction.

Melting point: 202-203°C.

5.4 threo-1-Azabicyclo[2.2.2]octyl(4-fluorophenyl)methanamine

30

According to the procedure described in 1.2, starting with 1.47 g (4.54 mmol) of (Z)-1-azabicyclo[2.2.2]octyl(4-fluorophenyl)methanone O-benzyloxime hydrochloride, 1 g of threo-1-azabicyclo[2.2.2]octyl(4-fluorophenyl)methanamine (diastereoisomeric excess, de=90%).

35

5.5 N-[(S)-(2S)-1-Azabicyclo[2.2.2]oct-2-yl(4-fluorophenyl)methyl]-2,6-dichloro-3-

(trifluoromethyl)benzamide hydrochloride 1:1

According to the procedure described in 1.3, starting
with 0.39 g (1.66 mmol) of threo-1-azabicyclo-
5 [2.2.2]octyl(4-fluorophenyl)methanamine, 0.5 g
(1.83 mmol) of 2,6-dichloro-3-trifluoromethylbenzoic
acid chloride, 0.25 g (1.83 mmol) of potassium
carbonate, 0.79 g of threo-*N*-[1-azabicyclo[2.2.2]oct-2-
yl(4-fluorophenyl)methyl]-2,6-dichloro-3-(trifluoro-
10 methyl)benzamide is obtained, after purification by
chromatography, in the form of an oil which is salified
with a solution of gaseous hydrochloric acid in ethyl
ether.

Melting point: 290-291°C.

15

The other compounds are obtained according to the
methods described in Examples 1, 2 and 5 from other
functionalized aldehydes.

20 The following Table 1 illustrates the chemical
structures of a few compounds of the invention.

In the "R" column, -CH=CH₂ denotes a vinyl group, in the
"R₁" column, C₆H₅ denotes a phenyl group and 4-C₆H₄N
25 denotes a quinolin-4-yl group. In the "Salt" column, -
denotes a compound in the base state, "HCl" denotes a
hydrochloride and "tfa" denotes a trifluoroacetate.


The compounds 14, 19 to 23, 24 of the table exist in
30 the hydrochloride or dihydrochloride form (see table)
solvated with one or more water molecules.

The compounds 15 and 16 of the table form a pair of
enantiomers which are separated by preparative HPLC
35 using a 20 µm CHIRACEL® AD column and, as solvent, a
95/5 isohexane/propan-2-ol mixture, likewise for the
compounds 17 and 18.

Table 2 gives the physical properties, the melting

points and optical rotations of the compounds of the table. "(d)" indicates a melting point with decomposition.

Table 1



No.	R ₁	R	X	n	R ₂	Salt	Stereochemistry
1	C ₆ H ₅	H	CH	1	3-SO ₂ N(CH ₃) ₂ , 4-Cl	-	threo (1R,2R;1S,2S)
2	C ₆ H ₅	H	CH	1	2-Cl, 5-CF ₃	HCl	threo (1R,2R;1S,2S)
3	C ₆ H ₅	H	CH	1	2-Cl, 3-CF ₃	HCl	threo (1R,2R;1S,2S)
4	C ₆ H ₅	H	CH	1	2,6-(Cl) ₂ , 3-CF ₃	HCl	threo (1R,2R;1S,2S)
5	C ₆ H ₅	H	CH	1	2-Cl, 3-CH ₃ , 6-F	HCl	threo (1R,2R;1S,2S)
6	C ₆ H ₅	H	CH	1	2-Cl, 3-CH ₃	HCl	threo (1R,2R;1S,2S)
7	C ₆ H ₅	H	CH	1	2,4,6-(Cl) ₃	HCl	threo (1R,2R;1S,2S)
8	C ₆ H ₅	H	CH	1	2-CH ₃ , 3-CF ₃	HCl	threo (1R,2R;1S,2S)

No.	R ₁	R	X	n	R ₂	Salt	Stereochemistry
9	C ₆ H ₅	H	CH	1	2,6-(Cl) ₂	HCl	threo (1R,2R;1S,2S)
10	C ₆ H ₅	H	CH	1	2,5-(CF ₃) ₂	HCl	threo (1R,2R;1S,2S)
11	C ₆ H ₅	H	CH	1	2-F, 3-Cl, 6-CF ₃	HCl	threo (1R,2R;1S,2S)
12	C ₆ H ₅	H	CH	1	2-CH ₃ , 3-Cl	HCl	threo (1R,2R;1S,2S)
13	C ₆ H ₅	H	CH	1	2,3-(Cl) ₂	HCl	threo (1R,2R;1S,2S)
14	4-C ₉ H ₆ N	CH=CH ₂	CH	1	2-Cl, 3-CF ₃	2HCl	(1S,2S)
15	C ₆ H ₅	H	CH	1	2-Cl, 3-CF ₃	tfa	(1R,2R)
16	C ₆ H ₅	H	CH	1	2-Cl, 3-CF ₃	tfa	(1S,2S)
17	C ₆ H ₅	H	CH	1	2,6-(Cl) ₂ , 3-CF ₃	HCl	(1S,2S)
18	C ₆ H ₅	H	CH	1	2,6-(Cl) ₂ , 3-CF ₃	HCl	(1R,2R)
19	C ₆ H ₅	H	N	1	2-Cl, 3-CF ₃	2HCl	threo (1R,2R;1S,2S)
20	C ₆ H ₅	H	N	1	2,6-(Cl) ₂ , 3-CF ₃	2HCl	threo (1R,2R;1S,2S)
21	C ₆ H ₅	H	N	1	2,6-(Cl) ₂	2HCl	threo (1R,2R;1S,2S)
22	C ₆ H ₅	H	N	1	2-CH ₃ , 3-CF ₃	2HCl	threo (1R,2R;1S,2S)
23	C ₆ H ₅	H	N	1	2-CH ₃ , 3-Cl	2HCl	threo (1R,2R;1S,2S)
24	C ₆ H ₅	H	CH	1	3,5 (Cl) ₂ ,4-NH ₂	HCl	threo (1R,2R;1S,2S)

No.	R ₁	R	X	n	R ₂	Salt	Stereochemistry
25	4-F-C ₆ H ₄	H	CH	1	2-Cl, 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
26	4-F-C ₆ H ₄	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
27	1-naphthyl	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
28	1-naphthyl	H	CH	1	2-Cl, 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
29	1-naphthyl	H	CH	1	2-CH ₃ , 3-Cl	HCl	threo (1R, 2R; 1S, 2S)
30	2-CH ₃ -C ₆ H ₄	H	CH	1	2-Cl, 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
31	2-CH ₃ -C ₆ H ₄	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
32	C ₆ H ₅	H	CH	1	6-CH ₃ , 3-Cl, 2-NH ₂	HCl	threo (1R, 2R; 1S, 2S)
33	C ₆ H ₅	H	CH	1	3, 6-(Cl) ₂ , 2-NH ₂	HCl	threo (1R, 2R; 1S, 2S)
34	C ₆ H ₅	H	CH	1	2, 6-(Cl) ₂ , 3-CH ₃	HCl	threo (1R, 2R; 1S, 2S)
35	C ₆ H ₅	H	CH	1	2-CH ₃ , 3-Cl	HCl	(1S, 2S)
36	C ₆ H ₅	H	CH	1	2-Cl, 3-CF ₃	HCl	erythro (1S, 2R; 1R, 2S)
37	4-F-C ₆ H ₄	H	CH	1	2-CH ₃ , 3-Cl	HCl	threo/erythro: 9/1
38	3-F-C ₆ H ₄	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
39	3-F-C ₆ H ₄	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	HCl	erythro (1S, 2R; 1R, 2S)
40	4-F, 3-CH ₃ -C ₆ H ₃	H	CH	1	2-CH ₃ , 3-OCH ₃	HCl	threo/erythro 1/1

No.	R ₁	R	X	n	R ₂	Salt	Stereochemistry
41	4-F, 3-CH ₃ -C ₆ H ₃	H	CH	1	3, 5-(OCH ₃) ₂	HCl	threo/erythro 1/1
42	4-F, 3-CH ₃ -C ₆ H ₃	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
43	3-F-C ₆ H ₄	H	CH	1	2-CH ₃ , 3-OCH ₃	HCl	threo (1R, 2R; 1S, 2S)
44	C ₆ H ₅	H	CH	1	2-OCH ₃ , 5-Cl	HCl	(1S, 2S)
45	C ₆ H ₅	H	CH	1	2-Br, 5-OCH ₃	HCl	(1S, 2S)
46	C ₆ H ₅	H	CH	1	2, 3-(OCF ₂ O)	HCl	(1S, 2S)
47	C ₆ H ₅	H	CH	1	2, 6-(OCH ₃) ₂	HCl	(1S, 2S)
48	C ₆ H ₅	H	CH	1	3, 5-(OCH ₃) ₂	HCl	(1S, 2S)
49	C ₆ H ₅	H	CH	1	2, 3-(OCH ₃) ₂	HCl	(1S, 2S)
50	C ₆ H ₅	H	CH	1	2-NH ₂ , 3-CH ₃	2HCl	(1S, 2S)
51	C ₆ H ₅	H	CH	1	2-OCH ₃ , 3, 6-(Cl) ₂	HCl	(1S, 2S)
52	C ₆ H ₅	H	CH	1	3-(O-C ₆ H ₅)	HCl	(1S, 2S)
53	C ₆ H ₅	H	CH	1	2, 5-(OCH ₃) ₂	HCl	(1S, 2S)
54	C ₆ H ₅	H	CH	1	2-CH ₃ , 3-OCH ₃	HCl	(1S, 2S)
55	C ₆ H ₅	H	CH	1	2-OCH ₃ , 3, 5-(Cl) ₂	HCl	(1S, 2S)
56	C ₆ H ₅	H	CH	1	2-Cl, 6-CH ₃	HCl	(1S, 2S)

No.	R ₁	R	X	n	R ₂	Salt	Stereochemistry
57	C ₆ H ₅	H	CH	1	2-NH ₂ , 6-CH ₃	2HCl	(1S, 2S)
58	C ₆ H ₅	H	CH	1	2-NH ₂ , 5-Br	2HCl	(1S, 2S)
59	C ₆ H ₅	H	CH	1	2-NH ₂ , 5-CH ₃	2HCl	(1S, 2S)
60	C ₆ H ₅	H	CH	1	2-OCH ₃ , 3-CH ₃	HCl	(1S, 2S)
61	C ₆ H ₅	H	CH	1	2-NH ₂ , 5-OCH ₃	2HCl	(1S, 2S)
62	C ₆ H ₅	H	CH	1	2-NH ₂ , 3-OCH ₃	2HCl	(1S, 2S)
63	C ₆ H ₅	H	CH	1	2-Cl, 5-CH ₃	HCl	(1S, 2S)
64	C ₆ H ₅	H	CH	1	2-OCH ₃ , 5-CH ₃	HCl	(1S, 2S)
65	C ₆ H ₅	H	CH	1	2-CH ₃ , 3-OH	HCl	(1S, 2S)
66	C ₆ H ₅	H	CH	1	2-CH ₃ , 5-Cl	HCl	(1S, 2S)
67	4-OCH ₃ -C ₆ H ₄	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	HCl	threo (1R, 2R; 1S, 2S)
68	4-OH-C ₆ H ₄	H	CH	1	2, 6-(Cl) ₂ , 3-CF ₃	-	threo (1R, 2R; 1S, 2S)
69	3-F-C ₆ H ₄	H	CH	1	2-CH ₃ , 3-Cl	HCl	threo (1R, 2R; 1S, 2S)

Table 2

No.	m.p. (°C)	$[\alpha]_D^{25}$ (°)
1	233-235	-
2	267-269	-
3	257-262	-
4	270-273	-
5	315-316	-
6	319-320	-
7	>300	-
8	281-283	-
9	359-361	-
10	281-283	-
11	347-349	-
12	311-313	-
13	316-318	-
14	185-205	-5.4 (c=0.986 MeOH)
15	196-197	-51.3 (c=1.03 MeOH)
16	214-215	+48.2 (c=0.618 MeOH)
17	264-268°C	+61.1 (c=0.32 MeOH)
18	265-268	-58.9 (c=0.3 MeOH)
19	207-208	-
20	214-215	-
21	210-211	-
22	215-217	-
23	210-212	-
24	336-339	-
25	271-273	-
26	290-291	-
27	317-318	-
28	314-315	-
29	315-316	-
30	215-230	-
31	210-220	-

No.	m.p. (°C)	$[\alpha]_D^{25}$ (°)
32	328-330	-
33	275-280	-
34	338-344	-
35	295-300	+55.2 (c=0.3 MeOH)
36	287-291	-
37	>300	-
38	232-234	-
39	289-291	-
40	124-126	-
41	154-156	-
42	254-256	-
43	280-282	-
44	162-164	+87.4 (c=0.32 ; MeOH)
45	275-277	+43.8 (c=0.32 ; MeOH)
46	191-193	+42.4 (c=0.32 ; MeOH)
47	234-236	+53.2 (c=0.30 ; MeOH)
48	297-299	+21.3 (c=0.31 ; MeOH)
49	284-286	+68.6 (c=0.32 ; MeOH)
50	244-246	+41.1 (c=0.30 ; MeOH)
51	194-196	+73.9 (c=0.29 ; MeOH)
52	105-108	+26.7 (c=0.30 ; MeOH)
53	169-171	+82.3 (c=0.30 ; MeOH)
54	298-300	+46.6 (c=0.31 ; MeOH)
55	213-215	+75.9 (c=0.30 ; MeOH)
56	331-333	+67.9 (c=0.31 ; MeOH)
57	295-297	+79.4 (c=0.30 ; MeOH)
58	244-246	+16.1 (c=0.30 ; MeOH)
59	282-284	+26.4 (c=0.31 ; MeOH)
60	235-237	+116.6 (c=0.29 ; MeOH)
61	278-280	+14.2 (c=0.30 ; MeOH)
62	264-266	+40.5 (c=0.30 ; MeOH)

No.	m.p. (°C)	$[\alpha]_D^{25}$ (°)
63	128-130	+61.9 (c=0.32 ; MeOH)
64	185-187	+81.9 (c=0.30 ; MeOH)
65	329-331	+45.9 (c=0.29 ; MeOH)
66	242-244	+8.4 (c=0.31 ; MeOH)
67	284-286	-
68		-
69	291-293	-

The compounds of the invention were subjected to a series of pharmacological trials which demonstrated their importance as substances with therapeutic activity.

5

Study of the transport of glycine in SK-N-MC cells expressing the native human transporter glyt1.

The capture of [^{14}C]glycine is studied in SK-N-MC cells (human neuroepithelial cells) expressing the native
10 human transporter glyt1 by measuring the radioactivity incorporated in the presence or in the absence of the test compound. The cells are cultured in a monolayer for 48 h in plates pretreated with fibronectin at 0.02%. On the day of the experiment, the culture medium
15 is removed and the cells are washed with a Krebs-HEPES ([4-(2-hydroxyethyl)piperiazine]1-ethanesulfonic acid) buffer at pH 7.4. After a preincubation of 10 min at 37°C in the presence either of buffer (control batch), or of test compound at various concentrations, or of 10
20 mM glycine (determination of the nonspecific capture), 10 μM [^{14}C]glycine (specific activity 112 mCi/mmol) are then added. The incubation is continued for 10 min at 37°C, and the reaction is stopped by 2 washes with a Krebs-HEPES buffer at pH 7.4. The radioactivity
25 incorporated by the cells is then estimated after adding 100 μl of liquid scintillant and stirring for 1 h. The counting is performed on a Microbeta Tri-luxTM counter. The efficacy of the compound is determined by the IC_{50} , the concentration of the compound which
30 reduces by 50% the specific capture of glycine, defined by the difference in radioactivity incorporated by the control batch and the batch which received the glycine at 10 mM.

35 The most active compounds of the invention, in this test, have an IC_{50} of the order of 0.001 to 10 μM .

The individual results for some compounds are as follows (IC_{50} in μM):

	Compound No. 3	0.017
	Compound No. 4	0.004
	Compound No. 14	0.07
5	Compound No. 17	0.001
	Compound No. 26	0.07

10 Study ex vivo of the inhibitory activity of a compound
on the capture of [¹⁴C]glycine in mouse cortical
homogenate

Increasing doses of the compound to be studied are administered by the oral route (preparation by trituration of the test molecule in a mortar in a
15 solution of Tween/Methocel™ at 0.5% in distilled water) or by the intraperitoneal route (dissolution of the test molecule in physiological saline or preparation by trituration in a mortar in a solution of Tween/Methocel™ at 0.5% in water, according to the
20 solubility of the molecule) to 20 to 25 g Iffa Crédo OF1 male mice on the day of the experiment. The control group is treated with the vehicle. The doses in mg/kg, the route of administration and the treatment time are determined according to the molecule to be studied.

25 After the animals have been humanely killed by decapitation at a given time after the administration, the cortex of each animal is rapidly removed on ice, weighed and stored at 4°C or frozen at -80°C (in both
30 cases, the samples are stored for a maximum of 1 day). Each sample is homogenized in a Krebs-HEPES buffer at pH 7.4 at a rate of 10 ml/g of tissue. 20 µl of each homogenate are incubated for 10 min at room temperature in the presence of 10 mM L-alanine and buffer. The
35 nonspecific capture is determined by adding 10 mM glycine to the control group. The reaction is stopped by filtration under vacuum and the retained radioactivity is estimated by solid scintillation by counting on a Microbeta Tri-lux™ counter.

An inhibitor of the capture of [^{14}C]glycine will reduce the quantity of radioligand incorporated into each homogenate. The activity of the compound is evaluated by its ED_{50} , the dose which inhibits by 50% the capture of [^{14}C]glycine compared with the control group.

The most potent compounds of the invention, in this test, have an ED_{50} of 0.1 to 5 mg/kg by the intraperitoneal route or by the oral route.

Study of the transport of glycine in mouse spinal cord homogenate

The capture of [^{14}C]glycine by the transporter glyt2 is studied in mouse spinal cord homogenate by measuring the radioactivity incorporated in the presence or in the absence of the compound to be studied.

After the animals have been humanely killed (Iffa Cr do OF1 male mice weighing 20 to 25 g on the day of the experiment), the spinal cord of each animal is rapidly removed, weighed and stored on ice. The samples are homogenized in a Krebs-HEPES ([4-(2-hydroxyethyl)piperazine]1-ethanesulfonic acid) buffer, pH 7.4, at a rate of 25 ml/g of tissue.

50 μl of homogenate are preincubated for 10 min at 25 C in the presence of Krebs-HEPES buffer, pH 7.4 and of compound to be studied at various concentrations, or of 10 mM glycine in order to determine the nonspecific capture. The [^{14}C]glycine (specific activity = 112 mCi/mmol) is then added for 10 min at 25 C at the final concentration of 10 μM . The reaction is stopped by filtration under vacuum and the radioactivity is estimated by solid scintillation by counting on a Microbeta Tri-luxTM counter.

The efficacy of the compound is determined by the concentration IC_{50} capable of reducing by 50% the

specific capture of glycine, defined by the difference in radioactivity incorporated by the control batch and the batch which received the 10 mM glycine.

- 5 The most active compounds of the invention in this test have an IC_{50} of the order of 0.02 to 10 μM .

The IC_{50} of the compound No. 17 is 0.69 μM .

- 10 The results of the trials carried out on the compounds of the invention of general formula (I) show that they are inhibitors of the glycine transporters glyt1 which are predominantly present in the brain, and of the glycine transporters glyt2, which are predominantly
15 present in the spinal cord.

- The compounds according to the invention can therefore be used for the preparation of medicaments, in particular of medicaments inhibiting the glycine
20 transporters glyt1 and/or glyt2.

- Thus, according to another of its aspects, the subject of the invention is medicaments which comprise a compound of formula (I), or an additional salt thereof
25 with a pharmaceutically acceptable acid, or a hydrate or a solvate of the compound of the formula (I).

- The compounds of the invention may be used in particular for the treatment of behavioral disorders
30 associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics, for the treatment of various forms of anxiety, panic attacks, phobias, obsessive-compulsive
35 disorders, for the treatment of various forms of depression, including psychotic depression, for the treatment of disorders due to alcohol abuse or to withdrawal from alcohol, sexual behavior disorders, food intake disorders, and for the treatment of

migraine.

Moreover, the compounds of the invention may be used for the treatment of painful muscular contractures in
5 rheumatology and in acute spinal pathology, for the treatment of spastic contractures of medullary or cerebral origin, for the symptomatic treatment of acute and subacute pain of mild to moderate intensity, for the treatment of intense and/or chronic pain, of
10 neurogenic pain and rebellious algia, for the treatment of Parkinson's disease and of Parkinsonian symptoms of neurodegenerative origin or induced by neuroleptics, for the treatment of primary and secondary generalized epilepsy, partial epilepsy with a simple or complex
15 symptomatology, mixed forms and other epileptic syndromes as a supplement to another antiepileptic treatment, or in monotherapy, for the treatment of sleep apnea, and for neuroprotection.

20 The subject of the present invention is also pharmaceutical compositions containing an effective dose of at least one compound according to the invention, in the form of a pharmaceutically acceptable base or salt or solvate, and in the form of a mixture,
25 where appropriate, with one or more suitable excipients.

Said excipients are chosen according to the pharmaceutical dosage form and the desired mode of
30 administration.

The pharmaceutical compositions according to the invention may thus be intended for oral, sublingual, subcutaneous, intramuscular, intravenous, topical,
35 intratracheal, intranasal, transdermal, rectal or intraocular administration.

The unit forms for administration may be, for example, tablets, gelatin capsules, granules, powders, oral or

injectable solutions or suspensions, patches or suppositories. For topical administration, it is possible to envisage ointments, lotions and collyria.

- 5 By way of example, a unit form for administration of a compound according to the invention in tablet form may comprise the following components:

	Compound according to the invention	50.0 mg
10	Mannitol	223.75 mg
	Croscarmellose sodium	6.0 mg
	Corn starch	15.0 mg
	Hydroxypropylmethylcellulose	2.25 mg
	Magnesium stearate	3.0 mg

15


Said unit forms contain doses in order to allow a daily administration of 0.01 to 20 mg of active ingredient per kg of body weight, according to the galenic form.

- 20 There may be specific cases where higher or lower dosages are appropriate; such dosages do not depart from the scope of the invention. According to the usual practice, the dosage appropriate for each patient is determined by the doctor according to the mode of
25 administration, the weight and the response of said patient.

- The present invention, according to its other aspects, also relates to a method for treating the pathologies
30 indicated above, which comprises the administration, to a patient, of an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts or the hydrates or solvates.

Claims

1. A compound corresponding to general formula (I)



5

in which

R represents a hydrogen atom or a vinyl group;

n represents 0 or 1 or 2 when R represents a hydrogen atom and n represents 1 when R represents a vinyl group;

10

X represents a group of formula CH or a nitrogen atom when R represents a hydrogen atom and X represents a group of formula CH when R represents a vinyl group;

R₁ represents either a phenyl or naphthyl group optionally substituted with one or more substituents chosen from halogen atoms, linear or branched (C₁-C₆)alkyl, hydroxyl and (C₁-C₆)alkoxy groups, the trifluoromethyl group, or a cyclohexyl group, or a heteroaryl group chosen from the thienyl, pyridinyl, oxazolyl, furanyl, thiazolyl, quinolinyl, and isoquinolinyl groups;

20

R₂ represents either a hydrogen atom, or one or more substituents chosen from halogen atoms and the trifluoromethyl, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, thienyl, phenyloxy, hydroxyl, mercapto, thio(C₁-C₆)alkyl and cyano groups or a group of general formula -NR₄R₅, SO₂NR₄R₅, -SO₂-(C₁-C₆)alkyl, -SO₂-phenyl, -CONR₄R₅, -COOR₇, -CO-(C₁-C₆)alkyl, -CO-phenyl, -NHCOR₈, -NHSO₂-(C₁-C₆)-

25

alkyl, -NHSO₂-phenyl and -NHSO₂NR₄R₅ or a group of formula -OCF₂O- attached at the 2- and 3-positions of the phenyl group;
the groups (C₁-C₆)alkyl, (C₁-C₆)alkoxy, -SO₂-(C₁-C₆)alkyl, -CO-(C₁-C₆)alkyl and -NHSO₂-(C₁-C₆)alkyl being optionally substituted with one or more groups R₃;
the groups phenyl, -SO₂-phenyl, -CO-phenyl and -NHSO₂-phenyl being optionally substituted with a group R₆;
R₃ represents a halogen atom, or a phenyl, (C₁-C₆)alkoxy or -NR₄R₅ group;
R₄ and R₅ represent, independently of each other, a hydrogen atom or a (C₁-C₆)alkyl group or R₄ and R₅ form with the nitrogen atom bearing them a pyrrolidine ring, a piperidine ring or a morpholine ring;
R₆ represents a hydrogen atom, a halogen atom, a trifluoromethyl group, a cyano group, a hydroxyl group, a mercapto group, a (C₁-C₆)alkyl or (C₁-C₆)alkoxy group;
R₇ represents a hydrogen atom or a (C₁-C₆)alkyl group optionally substituted with one or more groups R₃, or a phenyl group optionally substituted with a group R₆;
R₈ represents a (C₁-C₆)alkyl group optionally substituted with one or more groups R₃, or a (C₁-C₆)alkoxy group, or a phenyl group optionally substituted with a group R₆,
in the form of a free base or of an addition salt with an acid, of a hydrate or of a solvate.

2. The compound as claimed in claim 1, characterized in that it is of the threo configuration.

3. The compound as claimed in either of claims 1 and 2, characterized in that n represents 0 or 1.

4. The compound as claimed in claim 3, characterized in that X represents a group of formula CH.

5. The compound as claimed in claim 4, characterized in that R represents a hydrogen atom.

6. The compound as claimed in claim 5, characterized in that n represents 1.

7. The compound as claimed in claim 6, characterized in that R₁ represents an optionally substituted phenyl group.

8. A medicament, characterized in that it consists of a compound as claimed in one of claims 1 to 7.

10

9. A pharmaceutical composition, characterized in that it comprises a compound as claimed in one of claims 1 to 7, and at least one pharmaceutically acceptable excipient.

15

10. The use of a compound of formula (I) as claimed in one of claims 1 to 7 for the preparation of a medicament intended for the treatment of behavioral disorders associated with dementia, of psychoses, of various forms of anxiety, panic attacks, phobias, obsessive-compulsive disorders, of various forms of depression, of disorders due to alcohol abuse or to withdrawal from alcohol, sexual behavior disorders, food intake disorders, and of migraine.

25

11. The use of a compound of formula (I) as claimed in one of claims 1 to 7, for the preparation of a medicament intended for the treatment of contractures, of pain, of Parkinson's disease and of Parkinsonian symptoms, of epilepsy, of mixed forms and other epileptic syndromes as a supplement to another antiepileptic treatment, or in monotherapy, of sleep apnea, and for neuroprotection.

30